FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-30

Price

$14.43

+0.14%

Score6.2Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is exhibiting classic merger arbitrage price action following the recent announcement of its $4.8 billion acquisition by BioMarin. Despite a turbulent macro environment characterized by geopolitical panic and a VIX over 31, FOLD's exceptionally low annualized volatility (1.9%) and steady technical signals (QUIET_STORM, STEADY_CLIMB) confirm institutional absorption and supreme deal confidence. Crucially, the resilient credit market (OAS 0.9) ensures that financing for the acquisition remains intact, allowing the stock to act as a safe-haven cash proxy that completely ignores broader equity market chaos.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

Definitive M&A Catalyst: The pending $4.8 billion buyout by BioMarin has transformed FOLD into a pure merger arbitrage play, anchoring its price and driving it to a new 52-week high.
Macro Immunity: With the VIX elevated due to geopolitical shocks, FOLD is acting as a safe-haven; stable corporate credit markets (OAS 0.9) ensure BioMarin's deal financing is secure.
Technical Confirmation: Extremely low realized volatility (1.9%) and strong quantitative signals reflect institutional accumulation and a tightening deal spread.

← Back to 2026-03-30 View Full FOLD History →Yahoo Finance &nearr;